Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1065845-MDD3026 Adjunctive Treatment in Major Depressive Disorder
2024-519421-37-00Phase 3Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and persistent depressive disorder (PDD) comparing Adjunctive NBI-1065845 with Adjunctive placebo (2 arms). Primary endpoint: Change from baseline in MADRS total score at Day 56. Planned start Jul 2025; status: authorised.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)persistent depressive disorder (PDD)
Beyond the preview
Go deeper on 2024-519421-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519421-37-00.